This document is a project abstract that describes a study investigating the role of aldehyde dehydrogenase (ALDH) inhibition in elevating the efficacy of temozolomide (TMZ) in treating glioblastoma. The hypothesis is that inhibiting ALDH, which is associated with cancer stem cells and chemotherapy resistance, can improve TMZ treatment outcomes. The methods describe using diethylaminobenzaldehyde (DEAB) to inhibit ALDH activity in glioblastoma cell lines and tumors while treating with TMZ. Preliminary results show that DEAB combined with TMZ significantly reduced tumor growth compared to either treatment alone. The conclusions state that ALDH inhibition elevates TMZ efficacy.

1. TITLE
AUTHORS
Departments of Pediatrics, University of British Columbia, Vancouver, BC1;
INTRODUCTION ABSTRACT 6. Figure
Project abstract
RESULTS
7. Figure
1. Figure 4. Figure 7. ALDH inhibition elevates TMZ efficacy using DEAB
HYPOTHESIS 2. Figure CONCLUSIONS
Hypothesis
5. Figure
METHODS
1. Rock, K., McArdle, O., Forde, P., et al. A clinical review of treatment outcomes in glioblastoma multiforme-the validation in a
non-trial population of the result of a randomized Phase III clinical trial: has the more radical approach improved survival? Br J
Radiol. (2012) [Epub ahead of print] PMID: 22215883.
2. Das, S., Srikanth, M., & Kessler, J.A. Cancer stem cells and glioma. Nat Clin Pract Neurology, 4:427-435 (2008).
3. Marchitti, S.A., Brocker, C., Stagos, D., et al. Non-P450 aldehyde oxidiz- ing enzymes: The aldehyde dehydrogenase
superfamily. Expert Opin Drug Metab Toxicol 4:697–720 (2008).
4. Ma, I., & Allan, A.L. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev. 7(2):292-
306 (2011).
3. Figure (A)
SIGNIFICANCE
Poster significance
ACKNOWLEDGEMENTS
This research is supported by funding from the
Hannah’s Heroes Foundation, Brain Care BC
and the Canadian Institutes for Health Research.